Loading stock data…
McKesson Corporation (MCK)
$840.90+16.41 (+1.99%)
Market ClosedLast close Jul 24
McKesson Corporation provides healthcare services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
McKesson Corporation in the Healthcare sector is trading at $840.90 with a market capitalization of $87.9B. Wall Street consensus targets $945.47 (15 analysts), implying a +12.4% move over the next 12 months. The stock is currently 16% below its 52-week high of $999.00, remaining 1.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $96.30B↓ | $106.16B↑ | $103.15B↑ | $97.83B↑ | $90.82B |
| Gross Profit | $4.04B↑ | $3.69B↑ | $3.54B↑ | $3.28B↓ | $3.64B |
| Operating Income | $2.25B↑ | $1.66B↑ | $1.47B↑ | $1.08B↓ | $1.66B |
| Net Income | $1.68B↑ | $1.19B↑ | $1.11B↑ | $784.00M↓ | $1.26B |
Peer Comparison
JNJUNHPFE
Fundamentals
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$87.88B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.57
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.39%
ROE
Average efficiency. Growth may require heavy reinvestment.
-219.24%
Volume
Today's trading volume
633,281
Recent News
McKesson (MCK) Declares Quarterly Dividend, Is The Stock Still Undervalued?
McKesson (MCK) has announced a quarterly dividend of $0.94 per share, payable on October 1, 2026. Both the ex dividend and record dates are set for September 1, 2026, drawing fresh attention to the stock. See our latest analysis for McKesson. At a latest share price of $840.90, McKesson has seen a 1 day share price return of 1.99% and a 1 month share price return of 9.70%, while its 1 year total shareholder return of 18.61% and 5 year total shareholder return of 323.86% indicate solid longer...
McKesson (MCK) Stock May Still Be A Bargain After A 324% Run
McKesson stock has logged a very strong 323.9% return over the past five years, yet the latest valuation checks still flag it as screening on the cheap side. This raises the question of how much of the story is already reflected in the current US$840.90 share price. Over five years, McKesson has returned 323.9%, which puts long term holders in a strong position and makes today’s entry point more sensitive to the valuation starting point. For valuation, the key support is the company’s role...
Rising Dividend and Buybacks Might Change The Case For Investing In McKesson (MCK)
Earlier this week, McKesson Corporation announced a quarterly dividend of US$0.94 per share, payable on October 1, 2026, to shareholders of record as of the September 1, 2026 ex-dividend and record date. This higher payout highlights how McKesson is combining dividend growth with its existing share repurchase efforts, reinforcing management’s confidence in the company’s earnings power. Against this backdrop of a higher quarterly dividend, we’ll now examine how the announcement interacts with...
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs
RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.